Richard Kirkner

Rich Kirkner

Contributing Writer

Richard Kirkner is an award-winning journalist and editorial consultant who has specialized in ophthalmology and eye care media for three decades. Based in Philadelphia, his work has been recognized with more than 40 awards for editorial excellence.

  • All
  • Deals
  • Devices and Diagnostics
  • Digital
  • Genetics
  • Pharma
New J&J Vision CMO Steps onto a Very Large Stage

May 7 2020

New J&J Vision CMO Steps onto a Very Large Stage

The stage of ophthalmic innovation has hosted a multitude of new acts, people going from established companies to start-ups and vice versa and back again, ...
Read More
Covid-19 Impact on Healthcare Company Valuations & Financings

April 22 2020

Covid-19 Impact on Healthcare Company Valuations & Financings

The turmoil in the stock market over the past month or so has sent leading healthcare indices reeling, casting a cloud over the financing that ...
Read More
Verana eyes adding third registry

April 2 2020

Verana eyes adding third registry

The explosion of healthcare information technology has engendered a chaotic landscape of infinite terabytes of disparate but mutually relevant data segregated in infinite silos where ...
Read More
2020’s Potential Retina Milestones

February 26 2020

2020’s Potential Retina Milestones

As reports of intraocular inflammation and vasculitis have cast caution onto the uptake of the newest approved anti-VEGF drug, Novartis’ Beovu (brolucizumab), the quest to ...
Read More
Digging deep in the retina pipeline

November 13 2019

Digging deep in the retina pipeline

While Novartis’ recently approved Beovu soaked up a lot of the buzz in the retina space at the American Academy of Ophthalmology, reports of early ...
Read More
Biogen Jumps Back into Ophthalmology Gene Therapy with Nightstar Acquisition

March 13 2019

Biogen Jumps Back into Ophthalmology Gene Therapy with Nightstar Acquisition

It didn’t take Biogen long to jump back into ophthalmology after announcing its intention in December 2018 to terminate a collaborative agreement with Applied Genetic ...
Read More
Larry Haimovitch, 72, of Mill Valley, California

March 13 2019

Larry Haimovitch, 72, Journalist, Advisor and Ophthalmology Leader

Larry Haimovitch, 72, Journalist, Advisor and Ophthalmology Leader Larry Haimovitch, 72, husband of Carie Harris Haimovitch, of Mill Valley, California, died peacefully at home February ...
Read More
10 Takeaways from Roche-Spark Deal

February 27 2019

10 Takeaways from Roche’s $4.8 Billion Offer to Acquire Spark Therapeutics

Here are 10 things to know about Roche’s $4.8 billion bid to acquire Spark Therapeutics. Roche’s $114.5-a-share offer is a 122% premium over the closing ...
Read More
How Jim Thimons Helped Bring OIS’ Unique Approach to Talking About Innovation to Optometry and OIS@SECO 2019

February 14 2019

How Jim Thimons Helped Bring OIS’ Unique Approach to Talking About Innovation to Optometry and OIS@SECO 2019

When he attended his first Ophthalmology Innovation Summit at the American Society of Cataract and Refractive Surgery a few years ago, Jim Thimons, OD, recalls ...
Read More
Can 2019 Be ‘Transformative’ for AGTC?

January 16 2019

After XLRS Gene Therapy Disappoints, AGTC Looks to ‘Transformative Year’

Since announcing disappointing clinical trial results for one of its lead ophthalmic gene therapy candidates and the termination of its collaboration agreement with Biogen, Applied ...
Read More
Can Retina Candidates Find Their Place?

November 8 2018

Where Can Emerging Retina Agents Find Their Place in Clinical Practice?

Few therapeutic areas in medicine have a drug pipeline as flush as retina’s, as shown by trial results of a dozen or more emerging therapies ...
Read More
OIS@AAO Has a Record Year; So Does Ophthalmology Sector

November 1 2018

OIS@AAO Has a Record Year; So Does Ophthalmology Sector

CHICAGO – A record crowd gathered for the 10th anniversary of OIS@AAO last week in Chicago, and one of the highlights is always the Year ...
Read More